US2019099427A1PendingUtilityA1
Use of a dpp-4 inhibitor in podocytes related disorders and/or nephrotic syndrome
Est. expiryMay 14, 2032(~5.8 yrs left)· nominal 20-yr term from priority
A61P 9/00A61P 3/06A61P 9/12A61P 3/10A61P 3/08A61P 9/04A61P 43/00A61P 7/10A61P 9/10A61P 25/28A61P 3/04A61P 3/00A61P 27/12A61P 29/00A61P 1/16A61P 13/12A61P 13/00A61P 19/08A61P 13/02A61P 1/18A61P 15/00C07D 473/06A61K 31/18A61K 31/155A61K 45/06A61K 38/28A61K 31/522A61K 31/401A61K 31/4184
66
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
The present invention relates to methods for treating and/or preventing podocytes related disorders and/or nephrotic syndrome comprising the administration of an effective amount of a certain DPP-4 inhibitor, as well as to the use of a certain DPP-4 inhibitor for treating and/or preventing a metabolic disease in a patient with or at risk of podocytes related disorders and/or nephrotic syndrome.
Claims
exact text as granted — not AI-modifiedWhat is claimed is:
1 . A method of preventing, reducing the risk of or delaying the onset or progression micro- or macro-albuminaria, the onset of chronic kidney disease (CKD), the worsening of CKD, the onset of acute renal failure or death in a human type 2 diabetes patient, said method comprising administering linagliptin in a daily oral amount of 5 mg to the patient.
2 . The method according to claim 1 for delaying the onset or progression of micro- or macro-albuminuria in a human type 2 diabetes patient, said method comprising administering linagliptin in a daily oral amount of 5 mg to the patient.
3 . The method according to claim 2 , where in the duration of treatment is >=12 weeks.Join the waitlist — get patent alerts
Track US2019099427A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.